BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioLargo (BLGO) reported third-quarter 2026 revenue of $1,090,000, down slightly from a year earlier, as it continued investing in commercialization. Revenue declined 1%, while net loss narrowed 47% to $3,824,000, primarily because the prior year included a credit loss expense. Nine-month revenue fell 52% to $3,452,000, and net loss increased 2% to $11,229,000.
Nine-month operating cash use rose 22% to $8,182,000, although average monthly cash use declined approximately 26% in the third quarter versus the first half. Clyra Medical raised $4,299,000, primarily through debt; the battery subsidiary and parent also sold stock. Clyra signed distribution agreements and met a contractual milestone under an exclusive distribution agreement. BioLargo expects to shift spending from research and development toward sales in 2027, with an additional Clyra product line expected that year.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointClyra Medical raised $4,299,000, primarily through a debt offering, to fund its activities. 19% of market cap
- Moderate pointThird-quarter net loss narrowed 47% to $3,824,000, primarily reflecting a prior-year credit loss expense.
- Moderate pointBattery subsidiary stock sales raised $487,000; parent common-stock sales raised $1,359,000.
- Minor pointService revenue increased 72% in the third quarter and 23% over nine months versus year-earlier periods.
- Minor pointAverage monthly operating cash use fell approximately 26% to roughly $736,000 in Q3 from roughly $996,000 in the first half.
8 minor points
- Minor pointCorporate-segment operating loss declined 27% over nine months to $2,200,000 from $3,034,000.
- Minor pointClyra distribution agreements cover Advanced Solution for the U.S., Al-Hikma FZCO internationally, and Spartan Medical for U.S. government and military.
- Minor pointClyra completed a contractual milestone in the third quarter under an exclusive distribution agreement for certain products.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional Clyra product line is expected to roll out nationally in 2027 with a confidential partner.
- Minor point. Forward-looking: it has not happened yet and may not happen.2027 spending shift from research and development toward generating sales is BioLargo's stated expectation.
- Minor pointAEC water-treatment system has removed PFAS from municipal drinking water in Lake Stockholm, New Jersey, since January.
- Minor pointPFAS commercialization efforts include submitted bids and proposals, indications of interest, and partnership discussions.
- Minor pointEnergy and oil-sands water ventures are discussing investment and commercial scaling with potential partners.
Negative
- Major pointClyra's debt financing added debt and increased interest expense.
- Moderate pointNine-month revenue declined 52% to $3,452,000 from $7,148,000 a year earlier.
- Moderate pointNine-month operating cash use increased 22% to $8,182,000 from $6,707,000.
- Moderate pointNew stock issuance at the battery subsidiary and parent dilutes ownership at their respective levels.
- Minor pointThird-quarter revenue declined 1% to $1,090,000 from $1,103,000 a year earlier.
3 minor points
- Minor pointProduct revenue decreased 32% in the third quarter and 73% over nine months versus year-earlier periods.
- Minor pointNine-month net loss increased 2% to $11,229,000 from $11,047,000.
- Minor pointClyra Medical commercialization investment accounted for $6.4 million, approximately 57%, of the nine-month consolidated net loss.
News Explained
At
Sources and calculations
- BioLargo third-quarter 2026 results release (2026-11-17)
- BioLargo Q3 2026 fundamentals (2026-09-30)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,533,000 / ($2,209,000 / 92) = 63.8 days
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTMINSTER, CA / ACCESS Newswire / November 17, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences company, today reported financial results for the third quarter ended September 30, 2026, and provided an update on commercialization activities across its portfolio of companies. The company filed its Quarterly Report on Form 10-Q on November 16, 2026 (www.BioLargo.com/SEC-filings). The company will forego a quarterly earnings call, as its Annual Meeting of Stockholders will be held on December 1, 2026, in Aliso Viejo, California.
Net losses reflect continued investment in commercialization, led by Clyra Medical which accounted for
"We've focused our energies on investing to ensure 2027 is a breakout year for BioLargo, with new medical product lines and selling channels, a new consumer product line just launched under our brand name ‘barebird', and we continue developing and expanding important commercial relationships in the water and energy industries," said Dennis P. Calvert, BioLargo CEO. "We built the channels, the supply chain and partnerships, and most of this work was funded inside the subsidiaries rather than the parent. That is why we expect in 2027 to shift our spending away from R&D and toward generating sales, as we move from developing products to selling them."
FINANCIAL RESULTS
Total revenue was
Net loss was
Net cash used in operating activities was
BUSINESS OPERATIONS AND UPDATES
Readying for a new product launch next year, Clyra has focused sales efforts so far in 2026 on establishing distribution of its ViaCLYR wound irrigation product, signing distribution agreements with Advanced Solution for the U.S., Al-Hikma FZCO for international, and Spartan Medical for U.S. Government and military.
Clyra has made significant investments in personnel, processes, and skilled manufacturing capabilities while advancing product design, market testing, and clinical activities, and has expanded its outreach to clinicians and its participation in industry meetings. The clinician feedback has been positive, helping the company expand its commercial reach into health systems around the country and, ultimately around the world. These initiatives are designed to support existing distributors and position the company for the national rollout of an additional product line in collaboration with a confidential strategic partner. That momentum includes Clyra satisfying a contractual milestone in the third quarter under an exclusive distribution agreement for certain of its products.
In October 2026, BioLargo launched the "barebird" branded consumer odor products (www.barebird.com) through a newly formed subsidiary BioLargo CPG LLC. Focusing on pet and laundry odors, the products have no need for fragrances and, "smell like nothing... on purpose", and feature BioLargo's proprietary CupriDyne Clean technology used to control odors in landfills and trash facilities. Digital marketing utilizing modern AI selling tools will help focus marketing dollars to optimize BioLargo's return on investment.

BioLargo's "Aqueous Electrostatic Concentrator" (AEC) has been removing PFAS from municipal drinking water in Lake Stockholm, New Jersey since January. Both the Environmental Protection Agency and the New Jersey equivalent continue to monitor the AEC's performance to ensure it meets state and federal standards. "Attention has historically focused on federal drinking-water rulemaking, and that market is very much alive. Lawsuit settlements in the billions of dollars are expected to fund PFAS treatment at public water systems, much of it for projects not yet underway, and we're well positioned to compete for that work," said Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, Inc. "But drinking water was never the whole market. The requirements aren't receding. Based on our observations, they're spreading to wastewater, landfill leachate, biosolids, industrial pre-treatment and shorter-chain compounds. Industry is also paying attention to more than regulation. These billion-dollar settlements address harm to communities and public health, and any operator with PFAS in its waste stream can see that exposure. Increasingly, they're choosing to treat at the source now, regardless of when federal enforcement arrives."
BioLargo has submitted bids and proposals and received indications of interest from a wide range of customer types, has added several high-profile industry experts to its team, and has entered into discussions about partnership and collaboration with industry-leading firms that have a gap in their PFAS treatment product lines. BioLargo management believes these opportunities represent strong avenues for accelerating adoption of BioLargo's AEC technology.
The company has other development stage ventures in its portfolio - BioLargo Energy focused on the Cellinity industrial grid-scale battery, and Tu Nipi focused on water treatment solutions to help manage Canadian oil sands tailings water - which are actively engaged in discussions with potential strategic partners to invest and work together to scale commercial operations.
"In every market we serve - PFAS removal, grid-scale energy storage, infection control and wound care, industrial and household odor control - customers have lived with the drawbacks of the incumbent technologies because there hasn't been a better option," said Calvert. "Our products and solutions are designed to be that option - for our customers and for the partners who sell them."
Stockholders are encouraged to read the Company's Quarterly Report on Form 10-Q in its entirety, including the financial statements, the accompanying notes, and the discussion of liquidity and capital resources, which contain information not included in this release.
ANNUAL MEETING OF STOCKHOLDERS: DECEMBER 1, 2026
BioLargo will hold its Annual Meeting of Stockholders on Tuesday, December 1, 2026, beginning at 10:00 a.m. Pacific Time in Aliso Viejo, California. Stockholders of record are urged to vote their shares and to attend. Details are set forth in BioLargo's proxy statement filed October 19, 2026, and stockholders may contact the Company at Info@BioLargo.com for additional information about the meeting.
BioLargo values the opportunity to connect with its stockholders in person. Anyone who expects to be in the area on December 1st is encouraged to reach out to the Company in advance at the email address above so that we can coordinate a chance to meet with members of the management team.
RECENT ANNOUNCEMENTS
Additional detail on the developments described above is available in the Company's prior announcements:
BioLargo's BEST Expands Industrial PFAS Treatment Activities Amid Major PFAS Settlements - November 5, 2026
BioLargo Announces Launch of barebird.com - November 3, 2026
BioLargo's Clyra Medical Gains Commercial Traction as Clinician Enthusiasm Drives Health System Adoption - November 2, 2026
BioLargo Introduces barebird, a Company-Owned Brand, Reuniting Key Teams Behind Pooph's Consumer Market Success - October 28, 2026
BioLargo Canada and Tu Nipi Form Indigenous-Led Partnership to Treat Oil Sands Process Water and More - September 10, 2026
BioLargo's Subsidiary Clyra Medical Adds Third Distribution Channel Accelerating Commercial Rollout of ViaCLYR - September 3, 2026
BioLargo Signs Memorandum of Understanding with Aquatech to Accelerate Commercialization of PFAS Treatment Technology - May 4, 2026
A complete list of BioLargo announcements is available at www.biolargo.com.
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and commercialize them through company-owned brands, equity-held subsidiaries and channel partnerships. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Email: Info@BioLargo.com
Matt Kreps
Darrow Associates
214-597-8200
mkreps@darrowir.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements about the Company's capital needs, liquidity, availability of funds, business plans, and the commercialization of its technologies. Forward-looking statements are based on management's current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Those risks and uncertainties include, among others: the Company's history of net losses; its need for additional financing and possible limits on its access to capital markets; uncertainty about when it will become profitable; its reliance on third-party marketing partners, manufacturers and suppliers, and the absence of minimum purchase commitments from most customers; the risk that its technologies, including its liquid sodium battery, do not achieve market acceptance; the cost and uncertainty of obtaining FDA, EPA, state and foreign regulatory approvals; intense competition from larger, better-funded companies; and risks related to its common stock, including dilution from its equity line, stock-based payments and future financings, thin trading on the OTCQX, price volatility and penny stock rules. More information on these and other risks is included in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and in its other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement.
# # #
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were BioLargo's third-quarter 2026 revenue and net loss?
BioLargo reported $1,090,000 in revenue and a $3,824,000 net loss for the third quarter ended September 30, 2026. Revenue decreased 1% from a year earlier, while net loss decreased 47%, primarily because the prior-year quarter included a credit loss expense.
What does BioLargo expect for commercialization in 2027?
BioLargo expects to shift spending away from research and development toward generating sales in 2027, with a national rollout of an additional Clyra product line expected that year. The rollout involves a confidential partner.